Browsing Tag
hematologic oncology
3 posts
Why BTK inhibitor resistance is becoming a growth driver for Cellectar Biosciences, Inc. (NASDAQ: CLRB)
Can Cellectar Biosciences, Inc. turn BTK inhibitor resistance into an opportunity? Explore what iopofosine I 131 means for WM strategy.
Can BeOne’s sonrotoclax become the new backbone of B-cell cancer treatment?
Find out how BeOne Medicines’ sonrotoclax is redefining lymphoma and leukemia treatment with new ASH 2025 data.
Johnson & Johnson’s DARZALEX FASPRO shows 95% survival at 4 years in multiple myeloma
DARZALEX FASPRO shows 95% four-year PFS and deep MRD responses in NDMM, raising its profile as a foundational frontline therapy. Read the full trial analysis.